CRISPR Therapeutics has unveiled promising early data from its allogeneic CAR-T cell therapy CTX110, putting it into pole position in the obstacle-strewn race to develop the first off-the-shelf treatment for CD19+ B-cell malignancies.
Its Phase I CARBON trial showed a 58% overall response (ORR) rate, a 38% complete response (CR) rate and six-month...